Cingulate Inc.

NASDAQ: CING · Healthcare · Biotechnology

PublicHQ Kansas City, KS · WyandotteCIK 0001862150Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 31DQ —GM —SS 35

v0.1 · 35/100 weight · pillars only

↑ market scale, Piotroski F · ↓ return on equity, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$22.4M

Employees

as of 2026-08-20

Market cap

$71.0M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$22.4M-$22.4M2025

Operating income-$19.9M-$19.9M2025

Total assets$15.1M$15.1M2025

Liabilities$12.6M$12.6M2025

Equity$2.5M$2.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Cingulate Inc.’s financial profile?

Cingulate Inc. earned -$22.4M in FY2025 net income.

Peers · Healthcare

Dogwood Therapeutics, Inc.——Telomir Pharmaceuticals, Inc. Common Stock——RetinalGenix Technologies Inc.——Instinct Bio Technical Co. Holdings Inc.——PMV Pharmaceuticals, Inc.——OS Therapies Incorporated——

Neighbors

Wyandotte →

Bank of Labor Bancshares, Inc.$54.8M52D

Key facts

CEOShane J. Schaffer

SectorHealthcare

IndustryBiotechnology

HeadquartersKansas City, KS

ExchangeNASDAQ: CING

Employees14

IPO date2021-12-08

Latest filings

8-K2026-08-13 10-Q2026-08-13 8-K2026-07-23 8-K2026-07-14 8-K2026-07-02 8-K2026-06-16 8-K2026-06-02 DEF 14A2026-05-29

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.